Wikipedia

Acute decompensated heart failure

Acute decompensated heart failure (ADHF) is a sudden worsening of the signs and symptoms of heart failure, which typically includes difficulty breathing (dyspnea), leg or feet swelling, and fatigue.[1] ADHF is a common and potentially serious cause of acute respiratory distress. The condition is caused by severe congestion of multiple organs by fluid that is inadequately circulated by the failing heart. An attack of decompensation can be caused by underlying medical illness, such as myocardial infarction, an abnormal heart rhythm, infection, or thyroid disease.

Heart failure
Acute interstitial pulmonary edema. Note enlarged heart size, apical vascular redistribution ( circle ), and small bilateral pleural effusions ( arrow ).
SpecialtyCardiology Edit this on Wikidata

Acute Heart Failure

edit

Heart failure or cardiovascular insufficiency can be acute without being decompensated from a chronic condition. In this case, the signs of congestion such as weight gain and edema will not yet have developed. This is commonly due to pump failure or cardiovascular insufficiency after myocardial infarction when a significant loss of cardiac function occurs. Such patients will, have shortness of breath due to poor tissue perfusion, tissue hypoxia and metabolic acidosis. [2]

Signs and symptoms

edit

Cardiac symptoms of heart failure include chest pain/pressure and palpitations. Common noncardiac signs and symptoms of heart failure include loss of appetite, nausea, weight loss, bloating, fatigue, weakness, low urine output, waking up at night to urinate, and cerebral symptoms of varying severity, ranging from anxiety to memory impairment and confusion.[3]

Flash Pulmonary Edema

edit

Flash Pulmonary Edema or Crash Pulmonary Edema is a clinical characterization of acute heart failure with a dramatic presentation.[4] It is an acute cardiac disease precipitated by cardiac events and usually associated with severe hypertension.

Causes

edit

Chronic stable heart failure may easily decompensate. This most commonly results from an intercurrent illness (such as pneumonia), myocardial infarction (a heart attack), abnormal heart rhythms (such as atrial fibrillation), uncontrolled high blood pressure, or the person's failure to maintain a fluid restriction, diet, or medication.[5] Other well recognized precipitating factors include anemia and hyperthyroidism which place additional strain on the heart muscle. Excessive fluid or salt intake, and medication that causes fluid retention such as NSAIDs and thiazolidinediones, may also precipitate decompensation.[6]

Diagnosis

edit
 
A man with congestive heart failure and marked jugular venous distension. External jugular vein marked by an arrow.
 
Pitting edema during and after the application of pressure to the skin.

A jugular venous distension is the most sensitive clinical sign for acute decompensation.[7]

Treatment

edit

In acute decompensated heart failure, the immediate goal is to re-establish adequate perfusion and oxygen delivery to end organs. This entails ensuring that airway, breathing, and circulation are adequate. Management consists of propping up the head of the patient, giving oxygen to correct hypoxemia, administering morphine, diuretics like furosemide, addition of an ACE inhibitor, use of nitrates and use of digoxin if indicated for the heart failure and if arrhythmic.[8]

Oxygen

edit

Supplemental oxygen may be administered if blood levels of oxygen are low; the Heart Failure Society of America, however, has recommended that it not be used routinely.[8]

Medication

edit

Initial therapy of acute decompensated heart failure usually includes some combination of a vasodilator such as nitroglycerin, a loop diuretic such as furosemide, and non-invasive positive pressure ventilation (NIPPV).[9]

A number of different medications are required for people who are experiencing heart failure. Common types of medications that are prescribed for heart failure patients include ACE inhibitors, vasodilators, beta blockers, aspirin, calcium channel blockers, and cholesterol lowering medications such as statins. Depending on the type of damage a patient has suffered and the underlying cause of the heart failure, any of these drug classes or a combination of them can be prescribed. Patients with heart pumping problems will use a different medication combination than those who are experiencing problems with the heart's ability to fill properly during diastole. Potentially dangerous drug interactions can occur when different drugs mix together and work against each other.[10]

Vasodilators

edit

Nitrates such as nitroglycerin (glyceryl trinitrate) and isosorbide dinitrate are often used as part of the initial therapy for ADHF.[9]

Another option is nesiritide, although it should only be considered if conventional therapy has been ineffective or contraindicated as it is much more expensive than nitroglycerin and has not been shown to be of any greater benefit.[11]

A 2013 Cochrane review, compared nitrates and other pharmacological, non-pharmacological, and placebo interventions.[9] The review found no significant difference between the interventions in terms of symptom control or haemodynamic stability.[9]

The National Institutes for Health and Care Excellence (NICE) guidelines do not recommend routinely offering nitrates in acute heart failure.[12]

Diuretics

edit

Heart failure is usually associated with a volume overloaded state. Therefore, those with evidence of fluid overload should be treated initially with intravenous loop diuretics. In the absence of symptomatic low blood pressure intravenous nitroglycerin is often used in addition to diuretic therapy to improve congestive symptoms.[8]

Volume status should still be adequately evaluated. Some heart failure patients on chronic diuretics can undergo excessive diuresis. In the case of diastolic dysfunction without systolic dysfunction, fluid resuscitation may, in fact, improve circulation by decreasing heart rate, which will allow the ventricles more time to fill. Even if the patient is edematous, fluid resuscitation may be the first line of treatment if the person's blood pressure is low. The person may, in fact, have too little fluid in their blood vessels, but if the low blood pressure is due to cardiogenic shock, the administration of additional fluid may worsen the heart failure and associated low blood pressure. If the person's circulatory volume is adequate but there is persistent evidence of inadequate end-organ perfusion, inotropes may be administered. In certain circumstances, a left ventricular assist device (LVAD) may be necessary.

Once the person is stabilized, attention can be turned to treating pulmonary edema to improve oxygenation. Intravenous furosemide is generally the first line. However, people on long-standing diuretic regimens can become tolerant, and dosages must be progressively increased. If high doses of furosemide are inadequate, boluses or continuous infusions of bumetanide may be preferred. These loop diuretics may be combined with thiazide diuretics such as oral metolazone or intravenous chlorothiazide for a synergistic effect. Intravenous preparations are physiologically preferred because of more predictable absorption due to intestinal edema, however, oral preparations can be significantly more cost effective.[13]

Others

edit
ACE inhibitors and ARBs

The effectiveness and safety of ACE inhibitors and angiotensin receptor blockers (ARBs) acutely in ADHF have not been well studied, but are potentially harmful. A person should be stabilized before therapy with either of these medication classes is initiated.[14] Individuals with poor kidney perfusion are especially at risk for kidney impairment inherent with these medications.[15]

Beta-blockers

Beta-blockers are stopped or decreased in people with acutely decompensated heart failure and a low blood pressure. However, continuation of beta-blockers may be appropriate if the blood pressure is adequate.[16]

Inotropic agents

Inotropes are indicated if low blood pressure ( SBP < 90 mmHg ) is present.

The National Institutes for Health and Care Excellence (NICE) guidelines do not recommend routinely offering inotropes in acute heart failure.[12] However, they recommend it be considered in patients with ADHF and potentially reversible caradiogenic shock.[12]

Opioids

Opioids have traditionally been used in the treatment of the acute pulmonary edema that results from acute decompensated heart failure. A 2006 review, however, found little evidence to support this practice.[17]

The National Institutes for Health and Care Excellence (NICE) guidelines do not recommend routinely offering opioids in acute heart failure.[12]

Ventilation

edit

Continuous positive airway pressure may be applied using a face mask; this has been shown to improve symptoms more quickly than oxygen therapy alone,[18] and has been shown to reduce the risk of death.[19][20] Severe respiratory failure requires treatment with endotracheal intubation and mechanical ventilation.

Ultrafiltration

edit

Ultrafiltration can be used to remove fluids in people with ADHF associated with kidney failure. Studies have found that it decreases health care utilization at 90 days.[21] One such method is aquapheresis ultra-filtration

A 2022 Cochrane review on the benefits, efficacy, and safety of ultrafiltration compared to diuretic therapy found that ultrafiltration probably reduces the incidence of heart-failure related hospitalisation in the long term.[22]

The National Institutes for Health and Care Excellence (NICE) guidelines do not recommend routinely offering ultrafiltration in acute heart failure.[12]

Surgery

edit

In some cases, doctors recommend surgery to treat the underlying problem that led to heart failure.[23] Different procedures are available depending on the level of necessity and include coronary artery bypass surgery, heart valve repair or replacement, or heart transplantation. During these procedures, devices such as heart pumps, pacemakers, or defibrillators might be implanted. The treatment of heart disease is rapidly changing and thus new therapies for acute heart failure treatment are being introduced to save more lives from these massive attacks.[24]

Bypass surgery is performed by removing a vein from the arm or leg, or an artery from the chest and replacing the blocked artery in the heart. This allows the blood to flow more freely through the heart. Valve repair is where the valve that is causing heart failure is modified by removing excess valve tissues that cause them to close too tightly. In some cases, annuloplasty is required to replace the ring around the valves. If the repair of the valve is not possible, it is replaced by an artificial heart valve. The final step is heart replacement. When severe heart failure is present and medicines or other heart procedures are not effective, the diseased heart needs to be replaced.

Another common procedure used to treat heart failure patients is an angioplasty. Is a procedure used to improve the symptoms of coronary artery disease (CAD), reduce the damage to the heart muscle after a heart attack, and reduce the risk of death in some patients.[25]

A pacemaker is a small device that's placed in the chest or abdomen to help control abnormal heart rhythms.[26] They work by sending electric pulses to the heart to prompt it to beat at a rate that is considered to be normal and are used to treat patients with arrhythmias. They can be used to treat hearts that are classified as either a tachycardia that beats too fast, or a bradycardia that beats too slow.

See also

edit

References

edit
  1. ^ Allen LA, O'Connor CM (13 March 2007). "Management of acute decompensated heart failure". CMAJ. 176 (6): 797–805. doi:10.1503/cmaj.051620. PMC 1808524. PMID 17353535.
  2. ^ Neaverson, M. A. (1966-08-13). "Metabolic acidosis in acute myocardial infarction". British Medical Journal. 2 (5510): 383–385. doi:10.1136/bmj.2.5510.383. ISSN 0007-1447. PMC 1943592. PMID 5917356.
  3. ^ Heart Failure~clinical at eMedicine
  4. ^ Rimoldi, Stefano F.; Yuzefpolskaya, Melana; Allemann, Yves; Messerli, Franz (November 2009). "Flash Pulmonary Edema". Progress in Cardiovascular Diseases. 52 (3): 249–259. doi:10.1016/j.pcad.2009.10.002. PMID 19917337.
  5. ^ Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. (April 2008). "Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF". Archives of Internal Medicine. 168 (8): 847–854. doi:10.1001/archinte.168.8.847. PMID 18443260.
  6. ^ Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. (February 2005). "Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology". European Heart Journal. 26 (4): 384–416. doi:10.1093/eurheartj/ehi044. hdl:10400.16/493. PMID 15681577.
  7. ^ Torres M, Moayedi S (May 2007). "Evaluation of the acutely dyspneic elderly patient". Clin. Geriatr. Med. 23 (2): 307–25, vi. doi:10.1016/j.cger.2007.01.007. PMID 17462519.
  8. ^ a b c Heart Failure Society Of America (February 2006). "Evaluation and management of patients with acute decompensated heart failure". J. Card. Fail. 12 (1): e86–e103. doi:10.1016/j.cardfail.2005.11.017. PMID 16500576.
  9. ^ a b c d Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, et al. (Cochrane Heart Group) (August 2013). "Nitrates for acute heart failure syndromes". The Cochrane Database of Systematic Reviews. 2013 (8): CD005151. doi:10.1002/14651858.CD005151.pub2. PMC 8101690. PMID 23922186.
  10. ^ "Medications Commonly Used to Treat Heart Failure". American Heart Association. Retrieved 22 January 2010.
  11. ^ O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. (July 2011). "Effect of nesiritide in patients with acute decompensated heart failure". The New England Journal of Medicine. 365 (1): 32–43. doi:10.1056/NEJMoa1100171. hdl:10183/189579. PMID 21732835.
  12. ^ a b c d e "1 Recommendations | Acute heart failure: diagnosis and management | Guidance | NICE". www.nice.org.uk. 2014-10-08. Retrieved 2023-10-30.
  13. ^ Lau BD, Pinto BL, Thiemann DR, Lehmann CU (November 2011). "Budget impact analysis of conversion from intravenous to oral medication when clinically eligible for oral intake". Clinical Therapeutics. 33 (11): 1792–1796. doi:10.1016/j.clinthera.2011.09.030. PMID 22001356.
  14. ^ Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, et al. (December 2005). "Acute heart failure syndromes: current state and framework for future research". Circulation. 112 (25): 3958–3968. doi:10.1161/CIRCULATIONAHA.105.590091. PMID 16365214.
  15. ^ Valika AA, Gheorghiade M (March 2013). "Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature". Heart Failure Reviews. 18 (2): 135–140. doi:10.1007/s10741-011-9295-6. PMID 22213014. S2CID 44617135.
  16. ^ Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, et al. (September 2009). "B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode". European Heart Journal. 30 (18): 2186–2192. doi:10.1093/eurheartj/ehp323. PMID 19717851.
  17. ^ "Does the application of opiates, during an attack of Acute Cardiogenic Pulmonary Oedema, reduce patients' mortality and morbidity?". BestBets. Retrieved December 6, 2008.
  18. ^ Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J (July 2008). "Noninvasive ventilation in acute cardiogenic pulmonary edema". The New England Journal of Medicine. 359 (2): 142–151. doi:10.1056/NEJMoa0707992. PMID 18614781.
  19. ^ Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD (April 2006). "Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis". Lancet. 367 (9517): 1155–1163. doi:10.1016/S0140-6736(06)68506-1. PMID 16616558. S2CID 21490309.
  20. ^ Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, et al. (May 2010). "Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema". Annals of Internal Medicine. 152 (9): 590–600. doi:10.7326/0003-4819-152-9-201005040-00009. PMID 20439577. S2CID 207535976.
  21. ^ Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. (February 2007). "Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure". Journal of the American College of Cardiology. 49 (6): 675–683. doi:10.1016/j.jacc.2006.07.073. PMID 17291932.
  22. ^ Srivastava M, Harrison N, Caetano AF, Tan AR, Law M, et al. (Cochrane Heart Group) (January 2022). "Ultrafiltration for acute heart failure". The Cochrane Database of Systematic Reviews. 1 (1): CD013593. doi:10.1002/14651858.CD013593.pub2. PMC 8781783. PMID 35061249.
  23. ^ "Treatments and drugs for Heart Failure". Mayo Clinic. Retrieved 22 January 2010.
  24. ^ "Acute Heart Failures Definition And Management". Archived from the original on 15 January 2010. Retrieved 22 January 2010.
  25. ^ "What Is Coronary Angioplasty". National Heart Lung and Blood Institute. Retrieved 22 January 2010.
  26. ^ "What Is Coronary Angioplasty". National Heart Lung and Blood Institute. Retrieved 22 January 2010.
edit
Retrieved from "https://en.wiki.x.io/w/index.php?title=Acute_decompensated_heart_failure&oldid=1251384515"